Skip to content
Company Analysis

Emergent BioSolutions Inc. EBS

A comprehensive view of key metrics, scores, and financial health for Emergent BioSolutions Inc.

Overview of Emergent BioSolutions Inc.

EBS NYQ
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Small Cap
Emergent BioSolutions Inc. (EBS), is a Small Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $8.32, about 282.1% undervalued vs fair value, +33.1% 1Y return, ranked 525/1122 in sector.
Metrics Rev Growth -26.7% ROE 10.5%
USD 8.32
-0.83%
(Delayed)
• Vol 90d: 71.5%
52-Week Range
Market Cap
$432.90M
Enterprise Value
$799.60M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Weak
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Good
Valuation
Weak
Completeness: 82%
Confidence: 54%
Updated: Mar 8
Top Beats
No strong beats yet

Quick Facts

Website https://www.emergentbiosolutio...
HQ Gaithersburg, MD
Employees 900
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$29
$32
$35
Current: $8.32 +282% vs base

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$742.9M
-26.7%%
Gross Profit
$332.3M
4.6%%
R&D Expense
$53.2M
-24.8%%
Operating Income (EBIT)
$142.1M
297.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
120.1%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
4
Active Leaks
1/4
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Emergent BioSolutions Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
55
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
45
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing EBS's balance between Growth (18.1%), Profitability (37.7%), and Safety (44.2%). Growth 18% Safety 44% Profitability 38%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

30th percentile vs peers
30
Key Signals
EPS Growth YoY 75.8% 75p Revenue CAGR 3Y -11.6% 18p Rev Growth YoY -26.7% 10p
Strengths
  • D/E Ratio in top 20% of peers (1.09, 81th percentile)
  • Superior capital returns - 2 return metrics above peer median
  • Net Debt/EBITDA in top 20% of peers (15.29, 97th percentile)
Risks
  • Rev Growth YoY in bottom 20% of peers (-26.7%)
  • Growth below peer median (percentile: 30)

Profitability

63th percentile vs peers
63
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

74th percentile vs peers
74
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Emergent BioSolutions Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$31.79
- - -
+282.1% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000